Literature DB >> 15385538

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Sahng Wook Park1, Young-Ah Moon, Jay D Horton.   

Abstract

Lipid homeostasis is transcriptionally regulated by three DNA-binding proteins, designated sterol regulatory element-binding protein (SREBP)-1a, -1c, and -2. Oligonucleotide arrays hybridized with RNA made from livers of transgenic SREBP-1a, transgenic SREBP-2, and SREBP cleavage-activating protein knockout mice recently identified 33 genes regulated by SREBPs in liver, four of which had no known connection to lipid metabolism. One of the four genes was PCSK9, which encodes proprotein convertase subtilisin/kexin type 9a, a protein that belongs to the proteinase K subfamily of subtilases. Mutations in PCSK9 are associated with an autosomal dominant form of hypercholesterolemia. Here, we demonstrate that hepatic overexpression of either wild-type or mutant PCSK9 in mice results in hypercholesterolemia. The hypercholesterolemia is due to a post-transcriptional event causing a reduction in low density lipoprotein (LDL) receptor protein prior to the internalization and recycling of the receptor. Overexpression of PCSK9 in primary hepatocytes and in mice lacking the LDL receptor does not alter apolipoprotein B secretion. These data are consistent with PCSK9 affecting plasma LDL cholesterol levels by altering LDL receptor protein levels via a post-transcriptional mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385538     DOI: 10.1074/jbc.M410077200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  157 in total

1.  PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.

Authors:  Mali Liu; Guoxin Wu; Jennifer Baysarowich; Michael Kavana; George H Addona; Kathleen K Bierilo; John S Mudgett; Guillaume Pavlovic; Ayesha Sitlani; John J Renger; Brian K Hubbard; Timothy S Fisher; Celina V Zerbinatti
Journal:  J Lipid Res       Date:  2010-05-07       Impact factor: 5.922

2.  Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.

Authors:  Yajun Duan; Yuanli Chen; Wenquan Hu; Xiaoju Li; Xiaoxiao Yang; Xin Zhou; Zhinan Yin; Deling Kong; Zhi Yao; David P Hajjar; Lin Liu; Qiang Liu; Jihong Han
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

3.  Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.

Authors:  Sergio Fazio; Jessica Minnier; Michael D Shapiro; Sotirios Tsimikas; Patrizia Tarugi; Maurizio R Averna; Marcello Arca; Hagai Tavori
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

4.  Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.

Authors:  Gabrielle N Winston-McPherson; Haibo Xie; Ka Yang; Xiaoxun Li; Dongxu Shu; Weiping Tang
Journal:  Bioorg Med Chem Lett       Date:  2019-06-12       Impact factor: 2.823

5.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

Authors:  Ingrid K Kotowski; Alexander Pertsemlidis; Amy Luke; Richard S Cooper; Gloria L Vega; Jonathan C Cohen; Helen H Hobbs
Journal:  Am J Hum Genet       Date:  2006-01-20       Impact factor: 11.025

6.  PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.

Authors:  Xiaohui Xu; Yushang Cui; Lei Cao; Ye Zhang; Yan Yin; Xue Hu
Journal:  Exp Ther Med       Date:  2017-03-10       Impact factor: 2.447

7.  PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.

Authors:  Mary Cabell Jonas; Claudio Costantini; Luigi Puglielli
Journal:  EMBO Rep       Date:  2008-07-25       Impact factor: 8.807

8.  Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.

Authors:  Kévin Ly; Yascara Grisel Luna Saavedra; Maryssa Canuel; Sophie Routhier; Roxane Desjardins; Josée Hamelin; Janice Mayne; Claude Lazure; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

Review 9.  Lysine acetylation in the lumen of the ER: a novel and essential function under the control of the UPR.

Authors:  Mariana Pehar; Luigi Puglielli
Journal:  Biochim Biophys Acta       Date:  2012-12-13

10.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.